A Study of Two Formulations of LY3074828 in Healthy Participants
Status:
Completed
Trial end date:
2019-01-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the amount of the study drug, LY3074828, that gets
into the blood stream and how long it takes the body to get rid of LY3074828 when given as
different formulations. The tolerability of LY3074828 will also be evaluated and information
about any side effects experienced will be collected.
Screening is required within 28 days prior to the start of the study. For each participant,
the study will last about 12 weeks, not including screening.